We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.245 | 0.59% | 41.465 | 41.70 | 41.36 | 41.66 | 1,396,675 | 20:31:44 |
From Aug 2023 to Aug 2024
By Ian Walker
GSK has entered into an exclusive license agreement with Hansoh Pharmaceutical Group for its HS-20093 antibody-drug cancer treatment, with payments of up to $1.71 billion depending upon milestones being met.
The companies said Wednesday that GSK will make an initial upfront payment of $185 million to Hansoh with the rest depending upon success-based milestones for HS-20093.
Upon commercialization of HS-20093, GSK will pay tiered royalties on global net sales outside of China's mainland, Hong Kong, Macau, and Taiwan, the companies said in a joint statement.
HS-20093 is being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple phase I and II clinical trials in China.
GSK shares at 1248 GMT were up 13.60 pence, or 0.95 at 1,446.40 pence. They are currently up 0.6% over the year to date.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
December 20, 2023 08:12 ET (13:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
